首页 > 新闻 > 正文

国考

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

遗失的世界

A | 美国食品和药物管理局烟草产品中心主任Brian King在一份声明中说：“我们不会对制造商一再违反法律袖手旁观，尤其是在获得多次遵守的机会之后。”这些公司在销售烟草产品之前需要得到美国食品和药物管理局的许可，其中包括蒸汽烟和电子烟。

B | (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 。在过去的一年里，该机构一直在处理数百家生产电子烟的公司的申请，批准了少数几家，拒绝了许多其他公司。尽管如此，许多公司仍然继续生产和销售新产品，而没有经过FDA的程序。

C | 根据该声明，到目前为止，该机构只向它所说的违法公司发出警告信--迄今为止，它已发出近300封。

D | 但在许多情况下，这些信件并没有起到作用。根据Stat News的调查，警告信中提到的一半以上的产品今年夏天仍在市场上销售。美国食品和药物管理局说，面临禁令的六家公司已经收到警告，但继续销售未经授权的电子烟产品。这些公司位于明尼苏达州、西弗吉尼亚州、华盛顿州、佐治亚州、堪萨斯州和亚利桑那州。禁令标志着美国食品和药物管理局监督蒸汽烟和电子烟的方法发生了变化，并可能是对其他处于类似情况的公司的警告。该机构还有其他执法工具可供支配，包括有权发出罚款。面临禁令的六家公司可以同意一个两边同意的判决，这将“阻止他们直接或间接制造、销售或分销任何新的烟草产品，除非并直到满足某些先决条件”--包括要求这些产品获得FDA的授权。如果这些公司不同意，联邦机构可以要求法院阻止他们制造和销售产品。